Soligenix Dirección

Dirección controles de criterios 4/4

Soligenix's El consejero delegado es Christopher Schaber , nombrado en Aug 2006, tiene un mandato de 17.33 años. la remuneración anual total es $711.19K , compuesta por 70.2% salario y 29.8% primas, incluidas acciones y opciones de la empresa. posee directamente 0.058% de las acciones de la empresa, por valor de $3.73K . La antigüedad media del equipo directivo y del consejo de administración es de 9.5 años y 14.5 años respectivamente.

Información clave

Christopher Schaber

Chief Executive Officer (CEO)

US$700.5k

Compensación total

Porcentaje del salario del CEO	74.2%
Permanencia del CEO	17.7yrs
Participación del CEO	0.06%
Permanencia media de la dirección	9.8yrs
Promedio de permanencia en la Junta Directiva	14.8yrs

Actualizaciones recientes de la dirección

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

Soligenix's SGX942 flunks oral mucositis study in cancer patients, shares plummet 44%

Dec 22

Soligenix announces $20M strategic convertible debt financing agreement

Dec 16

Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters

Nov 20

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Christopher Schaber en comparación con los beneficios de Soligenix?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$700k	US$519k	-US$6m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$619k	US$453k	-US$9m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$674k	US$444k	-US$7m

Compensación vs. Mercado: La compensación total de Christopher ($USD711.19K) es aproximadamente el promedio para empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: La compensación de Christopher ha sido consistente con los resultados de la empresa en el último año.

CEO

Christopher Schaber (57 yo)

17.7yrs

Permanencia

US$700,485

Compensación

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Schaber	Chairman of the Board of Directors	17.7yrs	US$700.49k	0.057% $ 2.8k
Jonathan Guarino	Senior VP	4.6yrs	US$354.69k	0.0070% $ 341.2
Oreola Donini	Senior VP & Chief Scientific Officer	9.3yrs	US$387.59k	0% $ 0
Richard Straube	Senior VP & Chief Medical Officer	10.3yrs	US$249.94k	0.0051% $ 248.2

9.8yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: SNGXEl equipo directivo de la empresa es veterano y experimentado (9.5 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Schaber	Chairman of the Board of Directors	17.7yrs	US$700.49k	0.057% $ 2.8k
Jerome Zeldis	Independent Director	12.8yrs	US$72.50k	0.015% $ 710.7
Gregory Lapointe	Independent Director	15.1yrs	US$77.50k	0.0047% $ 228.6
Robert Rubin	Independent Director	14.5yrs	US$80.00k	0.0028% $ 136.1
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	sin datos	sin datos
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	sin datos	sin datos
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	sin datos	sin datos
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	sin datos	sin datos
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	sin datos	sin datos
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	sin datos	sin datos
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	sin datos	sin datos
Gary Wood	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	sin datos	sin datos

14.8yrs

Permanencia media

68.5yo

Promedio de edad

Junta con experiencia: SNGXLos consejos de administración de la empresa son veteranos y experimentados ( 14.5 años de permanencia media en el cargo).

Soligenix Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Insufficient new directors

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Insufficient new directors

Recent updates

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Consensus revenue estimates decrease by 11%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

New major risk - Share price stability

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 35% to US$3.25

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Consensus revenue estimates increase by 13%

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

No longer forecast to breakeven

Consensus revenue estimates decrease by 76%, EPS upgraded

No longer forecast to breakeven

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

Price target decreased to US$3.88

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Consensus forecasts updated

No longer forecast to breakeven

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of Its Covid-19 Vaccine in Non-Human Primates

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Soligenix Shares Preclinical Data Demonstrating That Its Thermostable Vaccine Platform May Be an Important Contributor to Addressing the Next Potential Pandemic and Future Health Emergencies

Soligenix, Inc. Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases

Consensus forecasts updated

Price target decreased to US$3.75

Second quarter 2021 earnings released: US$0.047 loss per share (vs US$0.10 loss in 2Q 2020)

Soligenix, Inc. announced delayed 10-Q filing